Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

Delayed Quote. Delayed Nasdaq - 04/24 04:00:00 pm
480.09 USD   +0.00%
04/10 REGENERON PHARM : to Report First Quarter 2015 Financial and Operati..
04/07 NASDAQ 100 MOVE : Viab, regn
03/27DJREGENERON PHARM : Correction on March 25 Regeneron Story
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Regeneron Pharmaceuticals : to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2015

04/10/2015 | 09:31am US/Eastern

TARRYTOWN, N.Y., April 10, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2015 financial and operating results on Thursday, May 7, 2015, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call Information
To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International). A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis. For additional information about the company, please visit

    Contact Information:

    Investor Relations               Corporate Communications

    Manisha Narasimhan, Ph.D.        Hala Mirza

    914.847.5126                     914.847.3422

To view the original version on PR Newswire, visit:

SOURCE Regeneron Pharmaceuticals, Inc.

React to this article
04/10 REGENERON PHARMACEUTICALS : to Report First Quarter 2015 Financial and Operating..
04/07 NASDAQ 100 MOVERS : Viab, regn
04/01 REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Receives FDA Approval f..
03/27DJREGENERON PHARMACEUTICALS : Correction on March 25 Regeneron Story
03/26DJREGENERON PHARMACEUTICALS : Correction to Headline on Wednesday's Regeneron Stor..
03/26 SANOFI : and Regeneron Release 18-Month Results of Odyssey Long Term Trial with ..
03/25DJRegeneron Wins Expanded Approval for Eye Drug Eylea
03/25 REGENERON PHARMACEUTICALS : EYLEA® (aflibercept) Injection Receives FDA Approval..
03/23 REGENERON PHARMACEUTICALS INC FILES (8-K) Disclosing Entry into a Material De..
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes